**Core tip:** Porto sinusoidal vascular liver disease (PSVD) and chronic portal vein thrombosis (PVT) are vascular liver diseases. This review aims to discuss the possibility that (PSVD) should be suspected in patients with PVT and to analyse the possible diagnostic tools able to differentiate between these two conditions. Moreover, the review focuses on the possible and relevant clinical consequences of missing a diagnosis of PSVD in patients with PVT.

INTRODUCTION
============

Porto sinusoidal vascular liver disease (PSVD) is a vascular liver disease characterized by portal hypertension in the absence of cirrhosis and other causes of liver disease\[[@B1]\]. Contrary to the Eastern World and Developing Countries, in the Western World PSVD is considered infrequent. However, a low grade of suspicion can contribute, at least partially, to the low frequency of PSVD in Western Countries. Indeed, in the last years, the deepening of the knowledge on PSVD and its clinical presentation led to the recognition of an increasing number of cases and to the awareness that, in the past, some patients affected by PSVD were misdiagnosed and classified as affected by cryptogenic cirrhosis\[[@B2]\]. Moreover, it has been recently shown that a number of disorders and drugs (Table [1](#T1){ref-type="table"}) are associated with PSVD\[[@B1],[@B2]\], and this observation suggests that an active search of signs of portal hypertension in patients affected by those diseases could lead to the identification of PSVD patients.

###### 

Diseases associated to porto sinusoidal vascular liver disease

  --------------------------------------------------------------------------------------------------------------------------------
  **Thrombophilia**
  Myeloproliferative neoplasm
  Protein S or C deficiency
  Antiphospholipid antibodies
  Lupus anticoagulant
  Factor V Leiden
  Prothrombin mutation
  **Hematologic disease**
  Myeloproliferative neoplasm (polycythemia vera, chronic myelogenous leukaemia, essential thrombocythemia)
  Myeloid metaplasia
  Lymphoproliferative conditions (Hodgkin's disease, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and multiple myeloma)
  Spherocytosis
  **Genetic disorders**
  Cystic fibrosis
  Adams Oliver syndrome
  Turner's disease
  **Autoimmune disease**
  Rheumatoid arthritis
  Systemic lupus erythematosus
  Systemic sclerosis
  Scleroderma
  **Gut diseases**
  Celiac disease
  Inflammatory bowel disease
  **Drug and toxics**
  Oxaliplatin
  Azathioprine
  6-thioguanine
  Arsenic
  Busulfan
  Cytosine arabinoside
  Cyclophosphamide
  Bleomycin
  Chlorambucil
  Doxyrubicin
  Carmustine
  **Acquired and congenital immunodeficiency**
  Human immunodeficiency virus
  Primary antibody-deficiency syndrome
  --------------------------------------------------------------------------------------------------------------------------------

Patients with portal vein thrombosis (PVT)
------------------------------------------

This review aims to discuss the possibility that PSVD should be suspected in patients with PVT. In fact, a particular relationship exists between PSVD and PVT. In a considerable number of patients\[[@B3]\], about 40%, PSVD is associated to prothrombotic conditions, including myeloproliferative disorders. The prothrombotic state may represent a pathogenic factor leading the occlusion of the small branches of the portal vein, contributing to the so called obliterative portal venopathy (Figure [1A](#F1){ref-type="fig"}), which is considered the primary histological lesion of PSVD\[[@B4]\]. In turn, in patients with PSVD, the prothrombotic state may favour, together with the low portal flow, the development of an extrahepatic portal vein thrombosis. PVT actually occurs in up to 40% of PSVD patients\[[@B5],[@B6]\], especially if a prothrombotic condition coexists. Whether the anticoagulant therapy is useful for the prevention of portal vein thrombosis or to improve the natural history of porto sinusoidal vascular liver disease idiopathic non-cirrhotic portal hypertension is still unknown\[[@B7]\].

![The three histologic features more frequent in porto sinusoidal vascular liver disease. A: Obliterative venopathy with small, rounded and fibrotic portal tracts, without evidence of the portal vein branch; B: Portal tract remnant; C: Nodular regeneration (parenchymal micronodular transformation is indicated with an asterisk).](WJH-11-613-g001){#F1}

The strong relationship between PSVD, hypercoagulability and incidence of PVT led to the hypothesis that a subset of patients with acute or chronic PVT could be affected by a pre-existing, undiagnosed PSVD. Actually, despite an active search\[[@B8]\] of local or systemic predisposing conditions (Table [2](#T2){ref-type="table"}), the cause of PVT is not recognizable in up to 25% of the patients. Moreover, in patients in whom a PVT is diagnosed, the evidence of a prothrombotic state usually leads to the diagnosis of a PVT secondary to that condition without taking into consideration the possibility of a pre-existing and undiagnosed PSVD. The possibility of missing a diagnosis of PSVD in a patient with PVT, especially if acute, may have relevant clinical consequences.

###### 

Predisposing causes of portal vein thrombosis

  **Systemic prothrombotic conditions**              **Recommended checks**
  -------------------------------------------------- -----------------------------------------------------------------------------------------------------
  **Inherited**                                      Resistance to activated C protein/molecular biology for
  Factor V Leiden                                    G1691A polymorphism
  Prothrombin gene mutation                          Molecular biology for G20210A polymorphism
  Protein C, protein S and antithrombin deficiency   Ratio with F II, V, VII or X after correction for vitamin K deficiency; family survey (recommended)
  **Acquired**                                       
  Antiphospholipid syndrome                          Anticardiolipin ELISA; LLAC
  Myeloproliferative neoplasm (MPN)                  JAK2 and CALR mutations; osteomidullary biopsy
  Paroxysomal nocturnal hemoglobinuria               Flow cytometry (deficient cells of CD55 and CD59)
  Oral contraceptive use                             Anamnesis
  Obesity                                            BMI \> 30 kg/m^2^
  CMV infection                                      CMV IgG, CMV IgM
  Pregnancy                                          Beta-HCG, anamnesis
  Celiac disease                                     Anti-transglutaminase IgA/IgG
  **Local prothrombotic conditions**                 Anamnesis and radiological examination
  **Surgery and trauma**                             
  Umbilical cannulation                              
  Splenectomy, cholecystectomy                       
  Hepatic resection                                  
  Abdominal trauma                                   
  Bariatric surgery                                  
  Portosystemic shunts including TIPS                Anamnesis and radiological examination
  **Inflammatory and infectious diseases**           
  Neonatal omphalitis                                
  Appendicitis, diverticulitis, pancreatitis         
  Inflammatory bowel disease                         
  Cholecystitis, cholangitis                         
  **Other**                                          
  Cirrhosis                                          
  Porto sinusoidal vascular liver disease            

LLAC: Lupus-like anticoagulant; ELISA: Enzyme-linked immunosorbent assay; BMI: Body mass index; CMV, Cytomegalovirus; HCG: Human chorionic gonadotropin; Ig: Immunoglobulin; TIPS: Transjugular portosystemic intrahepatic shunt.

Unfortunately, the distinction between these two conditions is not so easy and well defined, and the usefulness of liver biopsy to establish a differential diagnosis is questionable. In fact, while liver biopsy is adequate to exclude the presence of cirrhosis in patients with portal hypertension, the specific diagnostic features of PSVD are much more difficult to recognise\[[@B2]\]. More to the point, the histological distinction between the modification of the liver structure occurring in patients with PSVD (an intrahepatic cause of low portal perfusion) or PVT (in which the low portal perfusion is due to extrahepatic obstruction) may be difficult. Studies reporting a direct comparison of the histology features of PSVD and PVT are rare, mainly because the patients with PVT are not usually submitted to liver biopsy. Moreover, some modifications of liver histology, such as nodular regeneration and sinusoidal dilatation, could be due to compensatory adaptation to the reduction of portal flow that is common to both conditions. Verheij et al\[[@B4]\] compared liver biopsies from 70 patients with PSVD and 23 patients with PVT and observed that phlebosclerosis (*i.e*. obliterative portal venopathy), nodular regeneration and portal tract remnants (Figure [1A](#F1){ref-type="fig"}-[C](#F1){ref-type="fig"}) were significantly more frequent in patients with PSVD than in those with PVT, while portal vein dilatation was more frequently observed in patients with PVT. These results are in line with the hypothesis proposed by Wanless, which considers PSVD a microvascular disorder resulting from injury to the small portal vein branches, whereas PVT is, by definition, a macrovascular disorder. However, the applicability of the above described observations to the distinction of PVT secondary or not to PSVD in the single patient is arguable. In fact, histological features, such as sinusoidal dilatation, para-portal shunts and increased portal vessels, although with different prevalence, are actually observed in both conditions. Moreover, the inclusion of patients affected by a pre-existing PSVD in the PVT group in the study by Verheji et al\[[@B4]\] cannot be completely ruled out. Consequently, due to this existing bias, it is hard to really differentiate the first and the second group on the basis of histology.

Indeed, luminal narrowing and disappearance or sclerosis of the portal venous radicles are typical changes observed in the fibrotic portal tract of PSVD patients\[[@B9]\]. Moreover, according to the endothelial-mesenchymal transition theory proposed by Sato et al\[[@B10]\], which would explain in part the pathogenesis of the obliterative portal venopathy, an endothelial dysfunction is present in patients with PSVD. The vascular endothelial cells of portal venules acquire myofibroblastic features and start to synthesize type I collagen. Thus, as a consequence of the presence of a certain degree of liver fibrosis in patients with PSVD, it can be hypothesised that the use of liver stiffness measurement would be helpful to distinguish patients with PSVD and patients with PVT. The latter patients, at least theoretically, would be characterized by a lower liver stiffness. A higher liver stiffness was actually observed in a group of 22 patients affected by regenerative nodular hyperplasia in comparison with 13 patients with PVT\[[@B11],[@B12]\].

In patients with PVT, especially if acute, the correct identification of a pre-existing PSVD as the condition predisposing to PVT has relevant practical therapeutic implications. In fact, even in the absence of consistent clinical studies, in patients with PSVD, a lifelong anticoagulation is strongly suggested in presence of a prothrombotic condition and/or a portal vein thrombosis\[[@B13]\]. On the contrary, current guidelines on non-cirrhotic PVT do not suggest prolonging anticoagulation treatment lifelong in the absence of a prothrombotic state and/or extension of the thrombosis to mesenteric and splenic veins\[[@B13]\]. Thus, in a patient with PVT and an underlying undiagnosed PSVD without a prothrombotic state and without extension of the thrombosis to mesenteric and splenic veins, the anticoagulant therapy could be erroneously stopped once the PVT is resolved. However, as in PSVD, the slowing down of the portal flow is probably the principal condition leading to PVT, and as this condition is irreversible, the stop of anticoagulation may induce the rapid relapse of PVT.

Figure [2](#F2){ref-type="fig"} reports the computed tomography scan obtained in a 17-year-old male patient referred to our ward for acute portal vein thrombosis. Because of the negativity of any predisposing cause of portal vein thrombosis, including acquired and congenital prothrombotic states, he was treated with oral anticoagulation for only 1 year, and complete portal vein recanalization was documented at the computed tomography scan. However, after the withdrawal of anticoagulation, the patient had a rapid relapse of PVT with the extension of the thrombosis to splenic vein. The patient was firstly treated with low-molecular-weight-heparin and after with systemic thrombolysis with alteplase reaching the complete resolution of the thrombosis. With suspicion of porto sinusoidal vascular liver disease, the patient was submitted to liver biopsy, and finally the diagnosis of PSVD was made by observing perivenular and perisinusoidal fibrosis, sinusoidal dilatation, para-portal shunts and nodular regenerative hyperplasia.

![Contrast-enhanced computed tomography scan of a 17 year-old patient. A: Occlusive thrombosis of the trunk of portal vein; B: Complete resolution of the portal vein thrombosis after 1 year of anticoagulant therapy; C: Relapse of the portal vein thrombosis with extension to splenic vein 1 months after the stop of the anticoagulant therapy.](WJH-11-613-g002){#F2}

In conclusion, PSVD is probably a not so rare condition that should be actively searched not only by the hepatologists in the patients with signs of portal hypertension but also by the specialists who manage the patients affected by diseases associated with PSVD. Among the conditions associated with PSVD, PVT could be also included, and the suspicion of a pre-existing and missed PSVD should arise in any patient with PVT included (and maybe especially) in those affected by a prothrombotic state. However, more studies are needed to clarify the distinctive features of PSVD and PVT both histologically and elastographically, and new studies are needed to clarify the indications and the benefits of anticoagulant therapy in patients affected by PSVD.
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